Kerri Fitzgerald

DocwireNews

Large final geographic atrophy (GA) size may be associated with large choroidal neovascularization (CNV) size, according to data presented by Kerina Yang, BA, of VitreoRetinal Consultants in Brookline, MA, and colleagues and the American Academy of Ophthalmology 2020 Virtual meeting.Additionally, large CNV networks were associated with greater GA progression, carrying implications for visual outcomes.GA and CNV characteristics in patients receiving intravitreal injection treatment for age-related macular degeneration (AMD) have been reported in the past. In this study, the researchers looked at the correlation of size of GA as measured on en-face optical coherence tomography B (OCT-B) and size of the CNV on OCT-angiography study.They identified 297 consecutive patients who had received intravitreal &ldquo;treat and extend&rdquo; anti-vascular endothelial growth factor (VEGF) injection treatments for wet AMD between October 2016 and October 2019 and analyzed OCT-B and OCT-A studies. After excluding certain patients, 157 eyes of 139 patients were included. The researchers correlated OCT-A and en-face images with OCT-B images and blood flow views to confirm structural details.Of the 157 eyes, about half (49%) had an increase in GA through anti-VEGF treatment. Patients were classified as having mild (&lt;0.75 mm2), moderate (0.75-1.8 mm2), or marked (1.8 mm2 or greater) increases.About one-third of patients (32.5%) had mild increase in GA, with an average change in area of 0.31 mm2. About another third (35.1%) had moderate increase in GA, with average change in area of 1.21 mm2. The remaining third (32.5%) had marked increase, with an average change in area of 5.31 mm2.Large final areas of GA&mdash;those measuring 3 mm2 or more&mdash;correlated with 50% of large CNVs at presentation. Large CNVs were associated with greater initial GA areas (2.00 mm2 compared with 0.97 mm2 for small CNV and 0.58 mm2 for medium CNV), with 88.2% experiencing significant progression of GA. However, there was no association between the number or frequency of anti-VEGF injections and GA progression.The researchers also noted that 6.4% of eyes did not experience a change in their initial measurement of GA size, and 43.3% did not develop any GA through treatment. Interestingly, there were two eyes that appeared to have improvement in GA.&ldquo;Although a decrease in GA is rare, the two eyes were cases whether there was either patchy GA in the presence of shallow retinal pigment epithelium elevation or intraretinal and/or subretinal hyperreflectivity that made retinal pigment epithelium detail difficult to assess,&rdquo; the authors noted.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

GA Size, Progression Associated with CNV in Wet AMD

AAO 2020

Large final geographic atrophy (GA) size may be associated with large choroidal neovascularization (CNV) size, according to data presented by Kerina Yang, BA, of VitreoRetinal ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe